Additional Relevant Details On January 26, 2016 Theravance Biopharma announced the commercial launch of VIBATIV(R) in Canada for use as an antibiotic against Gram-positive bacteria.  VIBATIV will as be used to treat adult patients with certain types of pneumonia caused by the isolates of Staphylococcus aureus.  The Company will supply PENDOPHARM, a division of Pharmascience, Inc. with the antibiotic to be marketed and sold in Canada in return for future contingent payments and royalty on net sales.  This launch expands VIBATIV as a global product, in addition to being approved to market in the US, Europe and Russia.  The Company has also secured partners to market VIBATIV in Middle East, North Africa, Israel, China and India.